A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

Basit Öğe Kaydı
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorOzkalemkas, Fahir
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorAlacacioglu, Inci
dc.contributor.authorGuney, Tekin
dc.contributor.authorInce, Idris
dc.date.accessioned2024-02-23T14:02:29Z
dc.date.available2024-02-23T14:02:29Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractVenetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. (C) 2021 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clml.2021.04.004
dc.identifier.endpageE692en_US
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.issue8en_US
dc.identifier.pmid34059487en_US
dc.identifier.scopus2-s2.0-85107154198en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpageE686en_US
dc.identifier.urihttps://doi.org/10.1016/j.clml.2021.04.004
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11734
dc.identifier.volume21en_US
dc.identifier.wosWOS:000684596500017en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Lymphoma Myeloma & Leukemiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBcl2en_US
dc.subjectInhibitoren_US
dc.subjectVenetoclaxen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.subjectReal Lifeen_US
dc.titleA Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu